

## Ca<sup>2+</sup> signaling and cell death

Nada Dhaouadi<sup>a</sup>, Veronica Angela Maria Vitto<sup>b</sup>, Paolo Pinton<sup>b,c</sup>, Lorenzo Galluzzi<sup>d,e,f,\*</sup>, Saverio Marchi<sup>a,\*\*</sup>

<sup>a</sup> Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy

<sup>b</sup> Department of Medical Sciences, University of Ferrara, Ferrara, Italy

<sup>c</sup> GVM Care & Research, Maria Cecilia Hospital, Cotignola, Italy

<sup>d</sup> Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA

<sup>e</sup> Sandra and Edward Meyer Cancer Center, New York, NY, USA

<sup>f</sup> Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA

### ARTICLE INFO

#### Keywords:

Apoptosis

Bcl2

Endoplasmic reticulum, immunogenic cell death

Lysosomes

MPT-driven necrosis

### ABSTRACT

Multiple forms of regulated cell death (RCD) have been characterized, each of which originates from the activation of a dedicated molecular machinery. RCD can occur in purely physiological settings or upon failing cellular adaptation to stress. Ca<sup>2+</sup> ions have been shown to physically interact with – and hence regulate – various components of the RCD machinery. Moreover, intracellular Ca<sup>2+</sup> accumulation can promote organellar dysfunction to degree that can be overtly cytotoxic or sensitize cells to RCD elicited by other stressors. Here, we provide an overview of the main links between Ca<sup>2+</sup> and different forms of RCD, including apoptosis, mitochondrial permeability transition (MPT)-driven necrosis, necroptosis, ferroptosis, lysosome-dependent cell death, and parthanatos.

### 1. Introduction

Different cell death modalities exhibit specific morphological, biochemical, and immunological features, leading to the formulation of guidelines for the definition and comprehension of the cellular demise that are periodically revised and updated [1,2]. The term regulated cell death (RCD) is generally used to define an active cytotoxic program that relies on a specific molecular machinery, and hence can be modulated by genetic or pharmacological interventions [1]. RCD can occur in purely physiological conditions as part of a genetically encoded program for organismal development of homeostasis, and in such case is commonly referred to as programmed cell death (PCD) [3–5]. Alternatively, RCD can emerge upon failing cellular adaptation to detrimental changes of the intracellular or extracellular microenvironment. By eliminating dysfunctional or even potentially oncogenic cells, stress-induced RCD also contributes to the preservation of organismal homeostasis despite compromised cellular fitness [6,7]. Recently, cell death nomenclature has been refocused on quantitative and biochemical over qualitative and morphological aspects of the process, with terms including apoptosis, necroptosis, mitochondrial permeability transition (MPT)-driven

necrosis, parthanatos, ferroptosis and pyroptosis referring to precise molecular mechanisms [1].

The first connection between Ca<sup>2+</sup> signaling (Box 1) and cell death dates back to about 50 years ago, when it was proposed that ischemia-driven myocardial necrosis might be a consequence of excessive Ca<sup>2+</sup> entry into myocytes [8]. Nowadays, Ca<sup>2+</sup> ions have been involved in the regulation of a myriad of cellular processes including both the initiation and the execution steps of cell death as elicited by numerous stressors [9, 10]. Moreover, intracellular Ca<sup>2+</sup> overload constitutes a major perturbation of intracellular homeostasis that affects a variety of organelles and potentially culminates with or predisposes to RCD [11–13]. This implies that virtually all RCD variants can be influenced by intracellular Ca<sup>2+</sup> fluxes (Fig. 1).

Here, we provide an overview on the main links between Ca<sup>2+</sup> signaling and RCD.


### 2. Ca<sup>2+</sup> signaling and apoptotic cell death

Apoptosis is an RCD variant that involves the activation of one or more proteases of the caspase family, notably executioner caspase 3

\* Corresponding author at: Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.

\*\* Corresponding author.

E-mail addresses: [deadoc80@gmail.com](mailto:deadoc80@gmail.com) (L. Galluzzi), [s.marchi@univpm.it](mailto:s.marchi@univpm.it) (S. Marchi).



**Fig. 1.** The connection between  $\text{Ca}^{2+}$  signaling and cell death modalities. Multiple factors dictate cellular responses to  $\text{Ca}^{2+}$  fluxes, including (but not limited to): (1) The intensity, nature, and duration of  $\text{Ca}^{2+}$ -mobilizing stimuli, (2) expression levels of  $\text{Ca}^{2+}$  transporters,  $\text{Ca}^{2+}$ -buffering proteins and other components of the machinery for  $\text{Ca}^{2+}$  handling, and (3) compartmentalized  $\text{Ca}^{2+}$  kinetics and concentrations. Created with BioRender.com.

(CASP3) [13]. Beside playing a critical role in morphogenesis as a *bona fide* form of PCD, apoptosis participates in the etiology of numerous pathologies originating from the unbalanced loss of terminally differentiated cells, including cardiovascular conditions and neurological disorders [13]. Conversely, defects in apoptotic signaling have been consistently linked to malignant transformation and tumor progression [14,15]. At least in some experimental models, inhibiting  $\text{Ca}^{2+}$  efflux from the endoplasmic reticulum (ER) by blocking 1,4,5-trisphosphate receptors (IP<sub>3</sub>Rs) reportedly protects cells from apoptosis as induced by a variety of stimuli [16–18]. Most often, though, the impact of  $\text{Ca}^{2+}$  fluxes on apoptotic signaling has been investigated in more defined experimental systems.

So-called “extrinsic apoptosis” is generally initiated by the interaction of dedicated plasma receptors known as “death receptors” (DRs), such as Fas cell surface death receptor (FAS, also known as CD95), with their cognate ligands [19]. This results in the assembly of a supramolecular complex at the intracellular tail of DRs that promotes the sequential activation of CASP8 and CASP3, in some cases upon mitochondrial involvement and consequent release of cytochrome c, somatic (CYCS) [20]. FAS-driven apoptosis has been consistently associated with cytosolic  $\text{Ca}^{2+}$  elevations [21–23]. More specifically, FAS activation has been linked to a biphasic alteration in cytosolic  $\text{Ca}^{2+}$  levels: (1) a rapid  $\text{Ca}^{2+}$  discharge from the ER driven by the phospholipase C (PLC)-dependent production of the inositol IP<sub>3</sub> agonist inositol 1,4,5-trisphosphate (IP<sub>3</sub>) [22,24]; followed by (2) a delayed, sustained increase in cytosolic  $\text{Ca}^{2+}$  abundance [22,24]. However, while some authors suggest the latter to originate from the ER in response to the cytosolic accumulation of CYCS and promote apoptosis [22], others attribute delayed cytosolic  $\text{Ca}^{2+}$  waves elicited by DRs to extracellular stores under the control of ORAI calcium release-activated calcium modulator 1 (ORAI1) and stromal interaction molecule 1 (STIM1) and propose an anti-apoptotic role for them downstream of protein kinase C beta (PRKCB) activation [24,25]. These findings suggest that cytosolic  $\text{Ca}^{2+}$  elevations may have opposite effects on extrinsic apoptosis, potentially reflecting (1) the precise nature of the initiating stimulus, (2) expression levels of key components of the  $\text{Ca}^{2+}$  handling and/or apoptotic machinery; and (3) compartmentalized  $\text{Ca}^{2+}$  levels. In line with this notion, extracellular  $\text{Ca}^{2+}$  influx via transient receptor potential (TRP) channels sustains (rather than inhibits) apoptosis driven by tumor necrosis factor (TNF) in

hepatocellular carcinoma cells, with  $\text{Ca}^{2+}$ -mobilizing agents exacerbating TNF cytotoxic effects in the absence of mitochondrial involvement [26]. Conversely, TNF exerts neuroprotective effects against glutamate challenges, which are also associated with alterations of  $\text{Ca}^{2+}$  influx [27].

At odds with its extrinsic counterpart, intrinsic apoptosis is initiated by perturbations of the intracellular microenvironment (e.g., DNA damage) [28] and is demarcated by irreversible mitochondrial outer membrane permeabilization (MOMP) under control by pro- and anti-apoptotic members of the BCL2 apoptosis regulator (BCL2) protein family [13,29,30], followed by CASP3 activation [31–33]. MOMP as mediated by pore-forming BCL2 family members including BCL2 associated X, apoptosis regulator (BAX) and BCL2 antagonist/killer 1 (BAK1) is tightly linked to  $\text{Ca}^{2+}$  release from the ER via IP<sub>3</sub>Rs and consequent uptake by mitochondria [34–36]. Interestingly, BCL2 family apoptosis regulator BOK (BOK) not only can induce MOMP independent of BAX and BAK1 [37,38], but also resides at the ER [39], where it forms a complex with IP<sub>3</sub>Rs that preserves them from degradation [40,41]. That said, whether the pro-apoptotic functions of BOK involves alterations of ER  $\text{Ca}^{2+}$  efflux via IP<sub>3</sub>Rs remains to be fully elucidated [40,42–44]. In line with this notion, anti-apoptotic BCL2 family members including BCL2 itself and BCL2 like 1 (BCL2L1; best known as BCL-X<sub>L</sub>) robustly limit the transfer of  $\text{Ca}^{2+}$  ions from the ER to mitochondria, not only by lowering baseline ER  $\text{Ca}^{2+}$  levels [45–47], but also by (1) inhibiting IP<sub>3</sub>R opening [48–50], and (2) limiting mitochondrial  $\text{Ca}^{2+}$  accumulation via voltage-dependent anion channel 1 (VDAC1) [51,52]. Whether the latter mechanism is operation in all cells or whether at least in some instances anti-apoptotic BCL2 proteins instead promote mitochondria  $\text{Ca}^{2+}$  uptake via VDAC1, however, remains debated [53,54].

Importantly, various other oncogenic proteins and tumor suppressors share the ability to modulate the transfer of  $\text{Ca}^{2+}$  ions from the mitochondria to the ER [35,55–57] or control the activity of mitochondrial  $\text{Ca}^{2+}$  channels [58,59], resulting in altered RCD susceptibility. In line with this notion, genetic manipulation of major ER-mitochondria  $\text{Ca}^{2+}$  transfer effectors including the IP<sub>3</sub>R, VDACS and the mitochondrial calcium uniporter (MCU) complex has been shown to change the propensity of mammalian cells to undergo RCD in response to treatments that elicit cytosolic  $\text{Ca}^{2+}$  accumulation, including numerous chemotherapeutics [60–63]. That said (at least in some cellular settings), a

sustained transfer of  $\text{Ca}^{2+}$  ions from the ER to mitochondria does not culminate with RCD, but instead promotes the an irreversible proliferative arrest (i.e., cellular senescence) as a consequence of a  $\text{Ca}^{2+}$ -dependent remodeling of mitochondrial metabolism [64–66]. In this context, pharmacological BCL-X<sub>L</sub> inhibitors may act as senolytic agents not only because of their capacity to drive RCD in senescent cells [67,68], but also owing to their ability to concomitantly block the transfer of  $\text{Ca}^{2+}$  ions from the ER to mitochondria, which is supported by BCL-X<sub>L</sub> when expressed at low levels [69]. These observations also suggest that (1) cells with a high energetic demand (i.e., malignant cells) may intrinsically suffer from limitations in mitochondrial  $\text{Ca}^{2+}$  uptake [70] and (2) IP<sub>3</sub>R-mediated  $\text{Ca}^{2+}$  oscillations might increase cellular resistance to RCD-promoting insults.

Of note, mitochondrial permeabilization has also been suggested as a major cytotoxic effector of cytosolic  $\text{Ca}^{2+}$  waves as elicited by the opening of plasma membrane channels such as transient receptor potential cation channel subfamily V member 1 (TRPV1) [71,72] and ORAI1/STIM1 [73]. However, most of these studies fail to mechanistically address the implication of MOMP by genetic approaches, implying – that at least potentially – other RCD mechanisms may be involved (see below). Accordingly, BAX and BAK1 have been involved in RCD modalities other than apoptosis [74,75].

Taken together, these observations exemplify the key role of cytosolic  $\text{Ca}^{2+}$  as both an inducer and a regulator of apoptotic RCD.

### 3. $\text{Ca}^{2+}$ signaling and other forms of regulated cell death

#### 3.1. MPT-driven necrosis

Mitochondrial permeability transition (MPT)-mediated is a form of RCD driven by a sudden increase in the permeability of the inner mitochondrial membrane (IMM) to small solutes, leading to rapid mitochondrial transmembrane potential ( $\Delta\psi_m$ ) dissipation and consequent osmotic breakdown of the organelle [76]. The process is initiated by the opening of a hitherto poorly characterized multiprotein channel commonly known as permeability transition pore complex (PTPC) and is negatively regulated by peptidylprolyl isomerase F (PPIF, best known as CYPD) [76]. At least in some circumstances, mitochondrial  $\text{Ca}^{2+}$  overload coupled to reactive oxygen species (ROS) overproduction [77] induces increases PTPC conductance and hence drives MPT [78]. In line with this notion, various interventions affecting mitochondrial  $\text{Ca}^{2+}$  entry including manipulations of the MCU complex alter PTPC threshold for opening, hence affecting cellular sensitivity to MPT. Thus, deletion of *Mcu* – which encodes the pore-forming subunit of the MCU complex – has been shown to inhibit PTPC opening in both neurons and cardiomyocytes, at least in mice [79,80]. Conversely, interfering with the correct assembly of the MCU [81], deleting *McuB* (which encoded an MCU paralog) [82], as well as depleting mitochondrial calcium uptake 1 (MICU1) [83] reportedly increase mitochondrial  $\text{Ca}^{2+}$  uptake and lower PTPC threshold, resulting in cellular sensitization to MPT. Nevertheless, blocking the primary mechanism of mitochondrial  $\text{Ca}^{2+}$  efflux in the heart by deletion of *Slc8b1* imposed aberrant ROS production and necrotic death due to mitochondrial  $\text{Ca}^{2+}$  overload [84].

Of note, whole-body *Mcu* deletion as well as the cardiomyocyte-specific overexpression of a dominant-negative MCU variant does not mediate cardioprotective effects despite reduced mitochondrial  $\text{Ca}^{2+}$  levels [85,86]. This is probably due to the onset of compensatory mechanisms that preserve PTPC sensitivity to  $\text{Ca}^{2+}$ , including CYPD phosphorylation or increased CYPD binding to the F<sub>0</sub>F<sub>1</sub> ATP synthase [87], which plays a prominent role in PTPC formation [88–90]. Interestingly, MCU and the F<sub>0</sub>F<sub>1</sub> ATP synthase appear to form a megacomplex in various eukaryotes including human cells [91], but whether this interaction regulates MPT-driven necrosis remains to be elucidated.

Recently, the PLC activator 2,4,6-trimethyl-N-(m-3-trifluoromethylphenyl) benzenesulfonamide (m-3M3FBS) has been shown to evoke robust  $\text{Ca}^{2+}$  efflux from the ER coupled to mitochondrial  $\text{Ca}^{2+}$  uptake,

mitochondrial permeabilization and RCD in a BAX/BAK1-independent manner, suggesting the involvement of the MPT [92]. In line with this notion, such a process could be blocked with the CYPD inhibitor cyclosporine A (CsA) [92]. However, *Ppif* deletion had no impact on RCD as driven by m-3M3FBS [92], pointing to (1) a novel CYPD-independent activity of CsA, and (2) the existence of a mechanism of mitochondrial permeabilization other than MOMP and MPT [93].

#### 3.2. Necroptosis

Necroptosis is a form of caspase-independent RCD that involves the activation of the pore-forming protein mixed lineage kinase domain like pseudokinase (MLKL), which is generally mediated by receptor interacting serine/threonine kinase 3 (RIPK3) [94,95]. Importantly, altered  $\text{Ca}^{2+}$  homeostasis appears to be involved in multiple forms of necroptosis [96]. For instance, necroptosis as driven by TNF receptor superfamily member 1A (TNFRSF1A) signaling the context of caspase inhibition results in the MLKL-dependent activation of transient receptor potential cation channel subfamily M member 7 (TRPM7) and consequent  $\text{Ca}^{2+}$  influx [97]. Moreover, cytosolic  $\text{Ca}^{2+}$  accumulation as a consequence of ER stress [98] has been shown to drive necroptotic cell death in human leukemia cells exposed to an antimicrobial peptide [99]. Similarly, cardiomyocytes treated with sorafenib (a tyrosine kinase inhibitor currently used for cancer therapy) exhibit increased ER-mitochondria juxtaposition coupled to mitochondrial  $\text{Ca}^{2+}$  overload, RIPK3 and MLKL activation, and hence active necroptotic signaling [100,101]. In line with this notion, overexpression of sarcoendoplasmic reticulum  $\text{Ca}^{2+}$  ATPase (SERCA) pumps results in necroptosis inhibition upon improved  $\text{Ca}^{2+}$  storage in the ER and limited MCU-mediated mitochondrial  $\text{Ca}^{2+}$  entry [102]. MCU functions also appear to be potentiated by interactions with RIPK1 [103], pointing to a necroptosis-independent role of RIPK1 in the regulation of  $\text{Ca}^{2+}$  fluxes. Finally, RIPK3 overexpression in cardiomyocytes has been shown to promote cytosolic  $\text{Ca}^{2+}$  overload upon the establishment of ER stress, culminating necroptotic RCD [104]. Intriguingly, this cytotoxic effect could be at least partially rescued with CsA [104], suggesting the existence of functional interactions between the molecular machineries for MPT and necroptosis.

#### 3.3. Ferroptosis

Ferroptosis is an iron-dependent form of RCD involving abundant ROS generation and consequent peroxidative damage to lipids and other macromolecules [105,106]. In line with this notion, various antioxidant enzymes such as glutathione peroxidase 4 (GPX4), S100 calcium binding protein A4 (S100A4, best known as FSP1) and GTP cyclohydrolase 1 (GCH1) effectively limit lipid peroxidation, thus preventing ferroptosis [105,106]. A prolonged rise in cytosolic  $\text{Ca}^{2+}$  preceding complete cell rupture has been documented in multiple instances of ferroptosis [107]. Moreover, reducing reticular  $\text{Ca}^{2+}$  levels evokes a lipid remodeling that protects cells from ferroptosis [108]. Of note, the MCU regulator MICU1 appears to be required for lipid peroxidation during cold stress-induced ferroptosis [109], suggesting that mitochondrial  $\text{Ca}^{2+}$  uptake may also be involved in ferroptotic RCD. The underlying molecular mechanisms, however, remain to be fully understood.

#### 3.4. Lysosome-dependent cell death

Lysosome-dependent cell death is a form of RCD demarcated by primary lysosomal membrane permeabilization (LMP) and consequent spillage of lysosomal contents to the cytosol [1,110,111]. LMP can be driven by ROS overgeneration upon activation of lysosomal  $\text{Ca}^{2+}$  efflux channels [112]. Of note, lysosomal  $\text{Ca}^{2+}$  levels [113] resemble their reticular counterparts, playing a key role in the lysosomal functions. While the mechanisms through which lysosomal  $\text{Ca}^{2+}$  signaling influences lysosome-dependent cell death remain unclear, transmembrane

**Box 1****Fundamentals of Ca<sup>2+</sup> signaling**

Cytosolic Ca<sup>2+</sup> levels are tightly regulated, reflecting the central role of cytosolic Ca<sup>2+</sup> as a second messenger in multiple signaling pathways. Specifically, cytosolic Ca<sup>2+</sup> levels are low in resting cellular conditions (~100 nmol/L), as compared to the both extracellular environment (~2 mmol/L) and the lumen of intracellular Ca<sup>2+</sup> stores such as the endoplasmic reticulum (ER; 0.3–0.7 mmol/L), lysosomes (0.4–0.6 mmol/L) and Golgi apparatus (GA; 0.2–0.5 mmol/L) [121,122]. Such a tight control is ensured by complex toolkit involving channels, pumps, exchangers, transporters, and Ca<sup>2+</sup> binding proteins that are expressed at virtually all cellular compartments [123]. In response to a variety of stimuli, including extracellular transmitters and hormones, cytosolic Ca<sup>2+</sup> levels increase (i) via Ca<sup>2+</sup> influx from the extracellular milieu, which is mediated by plasma membrane channels including members of the transient receptor potential (TRP) and voltage-gated Ca<sup>2+</sup> (VGC) channel superfamilies [124,125]; or (ii) via Ca<sup>2+</sup> release from internal stores, mostly the ER and GA, upon activation of inositol 1,4,5-trisphosphate (IP<sub>3</sub>) receptors, lysosomes, upon activation of mucolipin TRP cation channel 1 (MCOLN1, best known as MCOLN1) and two pore segment channel 2 (TPCN2), and the sarcoplasmic reticulum (in myocytes), upon activation of ryanodine receptors [126].

The type of stimulus, its intensity and duration, as well as the presence of Ca<sup>2+</sup> buffering proteins and mitochondrial status determine cytosolic Ca<sup>2+</sup> levels achieved upon cellular stimulation. Cytosolic Ca<sup>2+</sup> levels are detected by dedicated sensors and ultimately translated into specific cellular responses. Free cytosolic Ca<sup>2+</sup> is rapidly captured by sarcoendoplasmic reticulum Ca<sup>2+</sup> ATPase (SERCA) pumps, which transfer Ca<sup>2+</sup> into the ER lumen, ATPase secretory pathway Ca<sup>2+</sup> transporting 1 (ATP2C1, best known as SPCA), which pumps Ca<sup>2+</sup> into the GA, and (to a smaller extent) lysosomes, which appear to accumulate Ca<sup>2+</sup> through an H<sup>+</sup>-dependent mechanism [127]. Alongside, Ca<sup>2+</sup> signaling is switched off by extrusion through ATPase plasma membrane Ca<sup>2+</sup> transporting 1 (ATP2B1, best known as PMCA) pump or solute carrier family 8 member A1 (SLC8A1, best known as NCX1) [128]. Of note, a slow, capacitive Ca<sup>2+</sup> influx from the extracellular space is necessary to refill intracellular stores. This is because PMCA works faster than refilling mechanisms, ultimately generating a process termed store-operated Ca<sup>2+</sup> entry (SOCE) [71]. Thus, upon ER Ca<sup>2+</sup> depletion, ER-resident members of the stromal interaction molecule (STIM) protein family oligomerize and redistribute to ER-plasma membrane junctions, where they recruit and activate ORAI calcium release-activated calcium modulator (ORAI). This enables the assembly of the core component of Ca<sup>2+</sup> release-activated Ca<sup>2+</sup> (CRAC) channels, which mediates Ca<sup>2+</sup> influx.

While mitochondria and peroxisomes limit cytosolic Ca<sup>2+</sup> elevations by sequestering high amounts of Ca<sup>2+</sup> ions, they are not considered constitutive Ca<sup>2+</sup> stores. In resting conditions, mitochondrial Ca<sup>2+</sup> levels resemble their cytosolic counterparts, but upon stimulation they can increase up to 10-fold. This is mainly due to the existence of an electric potential across the inner mitochondrial membrane (IMM), and the very close apposition of mitochondria to major intracellular Ca<sup>2+</sup> sources, particularly the ER [129]. In this setting, Ca<sup>2+</sup> ions readily cross the outer mitochondrial membrane (OMM) through voltage-dependent anion channels (VDACs), ultimately accumulating inside the matrix via the mitochondrial calcium uniporter (MCU) complex. Mitochondrial Ca<sup>2+</sup> signaling is terminated by the activity of two Ca<sup>2+</sup> efflux mechanisms, a Na<sup>+</sup>/Ca<sup>2+</sup> exchanger encoded by *SLC8B1* and a hitherto poorly identified H<sup>+</sup>/Ca<sup>2+</sup> antiporter.

BAX inhibitor motif containing 1 (TMBIM1) has recently been shown to increase lysosomal Ca<sup>2+</sup> content and thus promote lysosomal acidification, resulting in primary LMP and cell death during lysosomal stress [114].

### 3.5. Parthanatos

The term parthanatos refers to a caspase-independent type of RCD marked by poly(ADP-ribose) polymerase-1 (PARP1) hyperactivation and consequent translocation of apoptosis inducing factor mitochondria associated 1 (AIFM1) from mitochondria to the nucleus [106,115]. Similar to other RCD modalities, parthanatos has also been linked to altered Ca<sup>2+</sup> fluxes. Thus, increased cytosolic Ca<sup>2+</sup> levels have been associated with neuronal death as initiated by PARP1 activation [116]. Moreover, glutamate has been shown to trigger parthanatos upon activation of N-methyl-D-aspartate (NMDA) receptors, coupled to massive Ca<sup>2+</sup> influx [117]. In response to N-methyl-N'-nitro-N'-nitrosoguanidine (MNNG) administration and ischemia/reperfusion, parthanatos reportedly emerged from ER Ca<sup>2+</sup> spillage in concert with ROS overproduction [118]. However, additional work is required to clarify the mechanistic role of cytosolic Ca<sup>2+</sup> in parthanatos.

## 4. Conclusions

Although alterations of Ca<sup>2+</sup> signaling seem to participate in virtually all forms of cell death, the mechanistic contribution of Ca<sup>2+</sup> fluxes to RCD remains to be formally assessed in multiple settings, especially (but not only) for recently described RCD variants. Specifically, whether Ca<sup>2+</sup> fluxes are an active determinant of any steps of RCD as opposed to a passive phenomenon that accompanies (but does not affect) RCD has frequently been overlooked. Mechanistic experiments based on chelators of cytosolic and/or extracellular Ca<sup>2+</sup> ions, as well as genetic

perturbations of Ca<sup>2+</sup> buffering or transit at specific organelles stand out as critical approaches to precisely dissect the role of Ca<sup>2+</sup> in RCD. Alongside, it will be important to understand whether specific components of the cellular Ca<sup>2+</sup> handling machinery intersect with RCD signaling because of their role in Ca<sup>2+</sup> homeostasis or via other Ca<sup>2+</sup>-independent effects. Vice versa, it will be interesting to clarify whether components of the molecular machinery for RCD influence Ca<sup>2+</sup> homeostasis, and whether such an effect is linked to RCD signaling or not [119,120]. In conclusion, additional work is needed to fully elucidate the physical and functional interaction between Ca<sup>2+</sup> homeostasis and RCD.

### CRedit author statement

Nada Dhaouadi: Writing - Original draft preparation; Figures preparation. Veronica Angela Maria Vitto: Writing- Original draft preparation. Paolo Pinton: Writing- Reviewing and Editing. Lorenzo Galluzzi: Writing- Reviewing and Editing, Supervision. Saverio Marchi: Writing- Reviewing and Editing, Supervision.

### Declaration of Competing Interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: LG is/has been holding research contracts with Lytx Biopharma, Promontory and Onxeo, has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Imvax, Sotio, Promontory, Noxopharm, EduCom, and the Luke Heller TECPR2 Foundation, and holds Promontory stock options. All other authors have no conflicts to disclose.

## Data availability

No data was used for the research described in the article.

## Acknowledgments

PP is grateful to C. degli Scrovegni for her continuous support. VAMV is supported by the Italian Ministry of Health (SG-2021-12373911). PP is supported by the Italian Association for Cancer Research (IG-23670), A-ROSE, Progetti di Rilevante Interesse Nazionale (PRIN2017E5L5P3), and local funds from University of Ferrara. LG is/has been supported (as a PI unless otherwise indicated) by two Breakthrough Level 2 grants from the US DoD BCRP (#BC180476P1; #BC210945), by a Transformative Breast Cancer Consortium Grant from the US DoD BCRP (#W81XWH2120034, PI: Formenti), by a U54 grant from NIH/NCI (#CA274291, PI: Deasy, Formenti, Weichselbaum), by the 2019 Laura Ziskin Prize in Translational Research (#ZP-6177, PI: Formenti) from the Stand Up to Cancer (SU2C), by a Mantle Cell Lymphoma Research Initiative (MCL-RI, PI: Chen-Kiang) grant from the Leukemia and Lymphoma Society (LLS), by a Rapid Response Grant from the Functional Genomics Initiative (New York, US), by startup funds from the Dept. of Radiation Oncology at Weill Cornell Medicine (New York, US), by industrial collaborations with Lytix Biopharma (Oslo, Norway), Promontory (New York, US) and Onxeo (Paris, France), as well as by donations from Promontory (New York, US), the Luke Heller TECPR2 Foundation (Boston, US), Sotio a.s. (Prague, Czech Republic), Lytix Biopharma (Oslo, Norway), Onxeo (Paris, France), Ricerchiamo (Brescia, Italy), and Noxopharm (Chatswood, Australia). SM is supported by the Italian Ministry of Health (GR-2016-02364602), Nanoblend, and local funds from Marche Polytechnic University (Ancona, Italy).

The research leading to these results has received funding from the European Union - NextGenerationEU through the Italian Ministry of University and Research under PNRR - M4C2-I1.3 Project PE\_00000019 "HEAL ITALIA" to Saverio Marchi (SM), CUP I33C22006900006 (Marche Polytechnic University).

The views and opinions expressed are those of the authors only and do not necessarily reflect those of the European Union or the European Commission. Neither the European Union nor the European Commission can be held responsible for them.

## References

- [1] L. Galluzzi, I. Vitale, S.A. Aaronson, J.M. Abrams, D. Adam, P. Agostinis, E. S. Alnemri, L. Altucci, I. Amelio, et al., Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018, *Cell Death Differ.* 25 (2018) 486–541.
- [2] L. Galluzzi, et al., Essential versus accessory aspects of cell death: recommendations of the NCCD 2015, *Cell Death Differ.* 22 (2015) 58–73.
- [3] Y. Fuchs, H. Steller, Programmed cell death in animal development and disease, *Cell* 147 (2011) 742–758.
- [4] S. Nagata, M. Tanaka, Programmed cell death and the immune system, *Nat. Rev. Immunol.* 17 (2017) 333–340.
- [5] S. Bedoui, M.J. Herold, A. Strasser, Emerging connectivity of programmed cell death pathways and its physiological implications, *Nat. Rev. Mol. Cell Biol.* 21 (2020) 678–695.
- [6] L. Galluzzi, J.M. Bravo-San Pedro, O. Kepp, G. Kroemer, Regulated cell death and adaptive stress responses, *Cell. Mol. Life Sci. CMLS* 73 (2016) 2405–2410.
- [7] L. Galluzzi, T. Yamazaki, G. Kroemer, Linking cellular stress responses to systemic homeostasis, *Nat. Rev. Mol. Cell Biol.* 19 (2018) 731–745.
- [8] A. Fleckenstein, J. Janke, H.J. Doring, O. Leder, Myocardial fiber necrosis due to intracellular Ca overload—a new principle in cardiac pathophysiology, *Recent Adv. Stud. Cardiac. Struct. Metab.* 4 (1974) 563–580.
- [9] B. Zhivotovskiy, S. Orrenius, Calcium and cell death mechanisms: a perspective from the cell death community, *Cell Calcium* 50 (2011) 211–221.
- [10] R.M. La Rovere, G. Roest, G. Bultynck, J.B. Parys, Intracellular Ca(2+) signaling and Ca(2+) microdomains in the control of cell survival, apoptosis and autophagy, *Cell Calcium* 60 (2016) 74–87.
- [11] S. Orrenius, B. Zhivotovskiy, P. Nicotera, Regulation of cell death: the calcium-apoptosis link, *Nat. Rev. Mol. Cell Biol.* 4 (2003) 552–565.
- [12] B. Bonneau, J. Prudent, N. Popgeorgiev, G. Gillet, Non-apoptotic roles of Bcl-2 family: the calcium connection, *Biochim. Biophys. Acta* 1833 (2013) 1755–1765.
- [13] R. Singh, A. Letai, K. Sarosiek, Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins, *Nat. Rev. Mol. Cell Biol.* 20 (2019) 175–193.
- [14] B.A. Carneiro, W.S. El-Deiry, Targeting apoptosis in cancer therapy, *Nat. Rev. Clin. Oncol.* 17 (2020) 395–417.
- [15] S.T. Diepstraten, M.A. Anderson, P.E. Czabotar, G. Lessene, A. Strasser, G.L. Kelly, The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs, *Nat. Rev. Cancer* 22 (2022) 45–64.
- [16] S. Hudcová, J. Marková, V. Simko, L. Csáderová, T. Stracina, M. Sirova, M. Fojtů, E. Svastová, P. Grónesová, M. Pastorek, M. Nováková, D. Cholužová, J. Kopáček, S. Pastoreková, J. Sedláč, O. Krizánová, Sulforaphane-induced apoptosis involves the type 1 IP3 receptor, *Oncotarget* 7 (2016) 61403–61418.
- [17] H. Akl, G. Monaco, R. La Rovere, K. Welkenhuyzen, S. Kiviluoto, T. Vervliet, J. Molgo, C.W. Distelhorst, L. Missiaen, K. Mikoshiba, J.B. Parys, H. De Smedt, G. Bultynck, IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2, *Cell Death Dis.* 4 (2013) e632.
- [18] Y. Xue, J.L. Morris, K. Yang, Z. Fu, X. Zhu, F. Johnson, B. Meehan, L. Witkowski, E. Yasmeh, T. Golenar, M. Coatham, G. Morin, A. Monast, V. Pilon, P.O. Fiset, S. Jung, A.V. Gonzalez, S. Camilleri-Broet, L. Fu, L.M. Postovit, J. Spicer, W. H. Gotlieb, M.C. Guiot, J. Rak, M. Park, W. Lockwood, W.D. Foulkes, J. Prudent, S. Huang, SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca(2+) flux to mitochondria, *Nat. Commun.* 12 (2021) 5404.
- [19] A. Annibaldi, H. Walczak, Death receptors and their ligands in inflammatory disease and cancer, *Cold Spring Harb. Perspect. Biol.* 12 (2020), a036384.
- [20] C. Garrido, L. Galluzzi, M. Brunet, P.E. Puig, C. Didelot, G. Kroemer, Mechanisms of cytochrome c release from mitochondria, *Cell Death Differ.* 13 (2006) 1423–1433.
- [21] D. Boehning, D.B. van Rossum, R.L. Patterson, S.H. Snyder, A peptide inhibitor of cytochrome c/inositol 1,4,5-trisphosphate receptor binding blocks intrinsic and extrinsic cell death pathways, *Proc. Natl. Acad. Sci. U.S.A.* 102 (2005) 1466–1471.
- [22] A.L. Wozniak, X. Wang, E.S. Stieren, S.G. Scarbrough, C.J. Elferink, D. Boehning, Requirement of biphasic calcium release from the endoplasmic reticulum for Fas-mediated apoptosis, *J. Cell Biol.* 175 (2006) 709–714.
- [23] Y. Oshimi, S. Miyazaki, Fas antigen-mediated DNA fragmentation and apoptotic morphological changes are regulated by elevated cytosolic Ca2+ level, *J. Immunol.* 154 (1995) 599–609.
- [24] N. Khadra, L. Bresson-Bepoldin, A. Penna, B. Chaigne-Delalande, B. Segui, T. Levade, A.M. Vacher, J. Reiffers, T. Ducret, J.F. Moreau, M.D. Cahalan, P. Vacher, P. Legembre, CD95 triggers Orai1-mediated localized Ca2+ entry, regulates recruitment of protein kinase C (PKC) beta2, and prevents death-inducing signaling complex formation, *Proc. Natl. Acad. Sci. U.S.A.* 108 (2011) 19072–19077.
- [25] K. Airiau, P. Vacher, O. Micheau, V. Prouzet-Mauleon, G. Kroemer, M.A. Moosavi, M. Djavaheri-Mergny, TRAIL Triggers CRAC-dependent calcium influx and apoptosis through the recruitment of autophagy proteins to death-inducing signaling complex, *Cells* 11 (2021).
- [26] J. Zhu, M. Jin, J. Wang, H. Zhang, Y. Wu, D. Li, X. Ji, H. Yang, C. Yin, T. Ren, J. Xing, TNFalpha induces Ca(2+) influx to accelerate extrinsic apoptosis in hepatocellular carcinoma cells, *J. Exp. Clin. Cancer Res. CR* 37 (2018) 43.
- [27] A.M. Dolga, I. Granic, T. Blank, H.G. Knaus, J. Spiess, P.G. Luiten, U.L. Eisel, I. M. Nijholt, TNF-alpha mediates neuroprotection against glutamate-induced excitotoxicity via NF-kappaB-dependent up-regulation of K2.2 channels, *J. Neurochem.* 107 (2008) 1158–1167.
- [28] F.J. Groelly, M. Fawkes, R.A. Dagg, A.N. Blackford, M. Tarsounas, Targeting DNA damage response pathways in cancer, *Nat. Rev. Cancer* 23 (2023) 78–94.
- [29] S.J.F. Chong, S. Marchi, G. Petroni, G. Kroemer, L. Galluzzi, S. Pervaiz, Noncanonical cell fate regulation by Bcl-2 proteins, *Trends Cell Biol.* 30 (2020) 537–555.
- [30] P. Vandenabeele, G. Bultynck, S.N. Savvides, Pore-forming proteins as drivers of membrane permeabilization in cell death pathways, *Nat. Rev. Mol. Cell Biol.* (2022).
- [31] S. Marchi, E. Guilbaud, S.W.G. Tait, T. Yamazaki, L. Galluzzi, Mitochondrial control of inflammation, *Nat. Rev. Immunol.* 23 (2023) 159–173.
- [32] S.W. Tait, D.R. Green, Mitochondria and cell death: outer membrane permeabilization and beyond, *Nat. Rev. Mol. Cell Biol.* 11 (2010) 621–632.
- [33] F.J. Bock, S.W.G. Tait, Mitochondria as multifaceted regulators of cell death, *Nat. Rev. Mol. Cell Biol.* 21 (2020) 85–100.
- [34] L. Scorrano, S.A. Oakes, J.T. Opferman, E.H. Cheng, M.D. Sorcinelli, T. Pozzan, S. J. Korsmeyer, BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis, *Science* 300 (2003) 135–139.
- [35] G. Bustos, U. Ahumada-Castro, E. Silva-Pavez, A. Puebla, A. Lovy, J.C. Cardenas, The ER-mitochondria Ca(2+) signaling in cancer progression: fueling the monster, *Int. Rev. Cell Mol. Biol.* 363 (2021) 49–121.
- [36] A.M. Madec, J. Perrier, B. Panthou, F. Dingreville, Role of mitochondria-associated endoplasmic reticulum membrane (MAMs) interactions and calcium exchange in the development of type 2 diabetes, *Int. Rev. Cell Mol. Biol.* 363 (2021) 169–202.
- [37] F. Llambi, Y.M. Wang, B. Victor, M. Yang, D.M. Schneider, S. Gingras, M. J. Parsons, J.H. Zheng, S.A. Brown, S. Pelletier, T. Moldoveanu, T. Chen, D. R. Green, BOK Is a Non-canonical BCL-2 family effector of apoptosis regulated by ER-associated degradation, *Cell* 165 (2016) 421–433.
- [38] R. Shalaby, A. Diwan, H. Flores-Romero, V. Hertlein, A.J. Garcia-Saez, Visualization of BOK pores independent of BAX and BAK reveals a similar mechanism with differing regulation, *Cell Death Differ.* 30 (2023) 731–741.

- [39] N. Echeverry, D. Bachmann, F. Ke, A. Strasser, H.U. Simon, T. Kaufmann, Intracellular localization of the BCL-2 family member BOK and functional implications, *Cell Death Differ.* 20 (2013) 785–799.
- [40] J.J. Schulman, F.A. Wright, T. Kaufmann, R.J.H. Wojcikiewicz, The Bcl-2 protein family member Bok binds to the coupling domain of inositol 1,4,5-trisphosphate receptors and protects them from proteolytic cleavage, *J. Biol. Chem.* 288 (2013) 25340–25349.
- [41] J.J. Schulman, F.A. Wright, X. Han, E.J. Zluhan, L.M. Szczesniak, R. J. Wojcikiewicz, The stability and expression level of bok are governed by binding to Inositol 1,4,5-trisphosphate receptors, *J. Biol. Chem.* 291 (2016) 11820–11828.
- [42] J.J. Schulman, L.M. Szczesniak, E.N. Bunker, H.A. Nelson, M.W. Roe, L. E. Wagner 2nd, D.I. Yule, R.J.H. Wojcikiewicz, Bok regulates mitochondrial fusion and morphology, *Cell Death Differ.* 26 (2019) 2682–2694.
- [43] C.G. Bonzerato, K.R. Keller, J.J. Schulman, X. Gao, L.M. Szczesniak, R.J. H. Wojcikiewicz, Endogenous Bok is stable at the endoplasmic reticulum membrane and does not mediate proteasome inhibitor-induced apoptosis, *Front. Cell Dev. Biol.* 10 (2022), 1094302.
- [44] M.A. Carpio, R.E. Means, A.L. Brill, A. Sainz, B.E. Ehrlich, S.G. Katz, BOK controls apoptosis by Ca(2+) transfer through ER-mitochondrial contact sites, *Cell Rep.* 34 (2021), 108827.
- [45] P. Pinton, D. Ferrari, P. Magalhaes, K. Schulze-Osthoff, F. Di Virgilio, T. Pozzan, R. Rizzuto, Reduced loading of intracellular Ca(2+) stores and downregulation of capacitative Ca(2+) influx in Bcl-2-overexpressing cells, *J. Cell Biol.* 148 (2000) 857–862.
- [46] E.F. Eckenrode, J. Yang, G.V. Velmurugan, J.K. Foskett, C. White, Apoptosis protection by Mcl-1 and Bcl-2 modulation of inositol 1,4,5-trisphosphate receptor-dependent Ca2+ signaling, *J. Biol. Chem.* 285 (2010) 13678–13684.
- [47] C. White, C. Li, J. Yang, N.B. Petrenko, M. Madesh, C.B. Thompson, J.K. Foskett, The endoplasmic reticulum gateway to apoptosis by Bcl-X(L) modulation of the InsP3R, *Nat. Cell Biol.* 7 (2005) 1021–1028.
- [48] Y.P. Rong, G. Bultynck, A.S. Aromolaran, F. Zhong, J.B. Parys, H. De Smedt, G. A. Mignery, H.L. Roderick, M.D. Bootman, C.W. Distelhorst, The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor, *Proc. Natl. Acad. Sci. U.S.A.* 106 (2009) 14397–14402.
- [49] F. Zhong, M.W. Harr, G. Bultynck, G. Monaco, J.B. Parys, H. De Smedt, Y.P. Rong, J.K. Molitoris, M. Lam, C. Ryder, S. Matsuyama, C.W. Distelhorst, Induction of Ca (2+)–driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2-IP3 receptor interaction, *Blood* 117 (2011) 2924–2934.
- [50] N. Rosa, H. Ivanova, L.E. Wagner 2nd, J. Kale, R. La Rovere, K. Welkenhuyzen, N. Louros, S. Karamanou, V. Shabardina, I. Lemmens, E. Vandermarliere, K. Hamada, H. Ando, F. Rousseau, J. Schymkowitz, J. Tavernier, K. Mikoshiba, A. Economou, D.W. Andrews, J.B. Parys, D.I. Yule, G. Bultynck, Bcl-xL acts as an inhibitor of IP(3)R channels, thereby antagonizing Ca(2+)–driven apoptosis, *Cell Death Differ.* 29 (2022) 788–805.
- [51] G. Monaco, E. Decrock, N. Arbel, A.R. van Vliet, R.M. La Rovere, H. De Smedt, J. B. Parys, P. Agostinis, L. Leybaert, V. Shoshan-Barmatz, G. Bultynck, The BH4 domain of anti-apoptotic Bcl-XL, but not that of the related Bcl-2, limits the voltage-dependent anion channel 1 (VDAC1)-mediated transfer of pro-apoptotic Ca2+ signals to mitochondria, *J. Biol. Chem.* 290 (2015) 9150–9161.
- [52] S. Shimizu, Y. Shinohara, Y. Tsujimoto, Bax and Bcl-xL independently regulate apoptotic changes of yeast mitochondria that require VDAC but not adenine nucleotide translocator, *Oncogene* 19 (2000) 4309–4318.
- [53] H. Huang, X. Hu, C.O. Eno, G. Zhao, C. Li, C. White, An interaction between Bcl-xL and the voltage-dependent anion channel (VDAC) promotes mitochondrial Ca2+ uptake, *J. Biol. Chem.* 288 (2013) 19870–19881.
- [54] H. Huang, K. Shah, N.A. Bradbury, C. Li, C. White, Mcl-1 promotes lung cancer cell migration by directly interacting with VDAC to increase mitochondrial Ca2+ uptake and reactive oxygen species generation, *Cell Death Dis.* 5 (2014) e1482.
- [55] S. Marchi, C. Giorgi, L. Galluzzi, P. Pinton, Ca(2+) fluxes and cancer, *Mol. Cell* 78 (2020) 1055–1069.
- [56] A. Danese, S. Leo, A. Rimessi, M.R. Wieckowski, F. Fiorica, C. Giorgi, P. Pinton, Cell death as a result of calcium signaling modulation: a cancer-centric perspective, *Biochim. Biophys. Acta Mol. Cell Res.* 1868 (2021), 119061.
- [57] J. Loncke, A. Kaasik, I. Bezprozvanny, J.B. Parys, M. Kerkhofs, G. Bultynck, Balancing ER-mitochondrial Ca(2+) fluxes in health and disease, *Trends Cell Biol.* 31 (2021) 598–612.
- [58] R. Rizzuto, D. De Stefani, A. Raffaello, C. Mammucari, Mitochondria as sensors and regulators of calcium signalling, *Nat. Rev. Mol. Cell Biol.* 13 (2012) 566–578.
- [59] L. Modesti, A. Danese, V. Angela Maria Vitto, D. Ramaccini, G. Aguiari, R. Gafa, G. Lanza, C. Giorgi, P. Pinton, Mitochondrial Ca(2+) signaling in health, disease and therapy, *Cells* 10 (2021).
- [60] D. De Stefani, A. Bononi, A. Romagnoli, A. Messina, V. De Pinto, P. Pinton, R. Rizzuto, VDAC1 selectively transfers apoptotic Ca2+ signals to mitochondria, *Cell Death Differ.* 19 (2012) 267–273.
- [61] H. Ivanova, T. Vervliet, L. Missiaen, J.B. Parys, H. De Smedt, G. Bultynck, Inositol 1,4,5-trisphosphate receptor-isoform diversity in cell death and survival, *Biochim. Biophys. Acta* 1843 (2014) 2164–2183.
- [62] E. Penna, J. Espino, D. De Stefani, R. Rizzuto, The MCU complex in cell death, *Cell Calcium* 69 (2018) 73–80.
- [63] L. Galluzzi, J. Humeau, A. Buque, L. Zitvogel, G. Kroemer, Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors, *Nat. Rev. Clin. Oncol.* 17 (2020) 725–741.
- [64] C. Wiel, H. Lallet-Daher, D. Gitenay, B. Gras, B. Le Calve, A. Augert, M. Ferrand, N. Prevarskaya, H. Simonnet, D. Vindrieux, D. Bernard, Endoplasmic reticulum calcium release through ITPR2 channels leads to mitochondrial calcium accumulation and senescence, *Nat. Commun.* 5 (2014) 3792.
- [65] D.V. Ziegler, D. Vindrieux, D. Goehrig, S. Jaber, G. Collin, A. Griveau, C. Wiel, N. Bendridi, S. Djebali, V. Farfariello, N. Prevarskaya, L. Payen, J. Marvel, S. Aubert, J.M. Flaman, J. Rieusset, N. Martin, D. Bernard, Calcium channel ITPR2 and mitochondria-ER contacts promote cellular senescence and aging, *Nat. Commun.* 12 (2021) 720.
- [66] V. Farfariello, D.V. Gordienko, L. Meslimany, Y. Touil, E. Germain, I. Fliniaux, E. Desruelles, D. Gkika, M. Roudbaraki, G. Shapovalov, L. Noyer, M. Lebas, L. Allart, N. Zienthal-Gelus, O. Iamshanova, F. Bonardi, M. Figeac, W. Laine, J. Kluzza, P. Marchetti, B. Quesnel, D. Metzger, D. Bernard, J.B. Parys, L. Lemonnier, N. Prevarskaya, TRPC3 shapes the ER-mitochondria Ca(2+) transfer characterizing tumour-promoting senescence, *Nat. Commun.* 13 (2022) 956.
- [67] J. Chang, Y. Wang, L. Shao, R.M. Labege, M. Demaria, J. Campisi, K. Janakiraman, N.E. Sharpless, S. Ding, W. Feng, Y. Luo, X. Wang, N. Aykin-Burns, K. Krager, U. Ponnappan, M. Hauer-Jensen, A. Meng, D. Zhou, Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice, *Nat. Med.* 22 (2016) 78–83.
- [68] Y. Jia, L. Han, C.L. Ramage, Z. Wang, C.C. Weng, L. Yang, S. Colla, H. Ma, W. Zhang, M. Andreeff, N. Daver, N. Jain, N. Pemmaraju, K. Bhalla, S. Mustjoki, P. Zhang, G. Zheng, D. Zhou, Q. Zhang, M. Konopleva, Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells, *Haematologica* (2023).
- [69] J. Yang, H. Vais, W. Gu, J.K. Foskett, Biphasic regulation of InsP3 receptor gating by dual Ca2+ release channel BH3-like domains mediates Bcl-xL control of cell viability, *Proc. Natl. Acad. Sci. U.S.A.* 113 (2016) E1953–E1962.
- [70] C. Cardenas, A. Lovy, E. Silva-Pavez, F. Urria, C. Mizzone, U. Ahumada-Castro, G. Bustos, F. Jana, P. Cruz, P. Farias, E. Mendoza, H. Huerta, P. Murgas, M. Hunter, M. Rios, O. Cerda, I. Georgakoudi, A. Zakarian, J. Molgo, J.K. Foskett, Cancer cells with defective oxidative phosphorylation require endoplasmic reticulum-to-mitochondria Ca(2+) transfer for survival, *Sci. Signal.* 13 (2020).
- [71] G. Shapovalov, D. Gordienko, N. Prevarskaya, Store operated calcium channels in cancer progression, *Int. Rev. Cell Mol. Biol.* 363 (2021) 123–168.
- [72] K. Zhai, A. Liskova, P. Kubatka, D. Busselberg, Calcium entry through TRPV1: a potential target for the regulation of proliferation and apoptosis in cancerous and healthy cells, *Int. J. Mol. Sci.* 21 (2020).
- [73] J. Tanwar, R.K. Motiani, Role of SOCE architects STIM and Orai proteins in Cell Death, *Cell Calcium* 69 (2018) 19–27.
- [74] J. Karch, J.Q. Kwong, A.R. Burr, M.A. Sargent, J.W. Elrod, P.M. Peixoto, S. Martinez-Caballero, H. Osinska, E.H. Cheng, J. Robbins, K.W. Kinnally, J. D. Molkenint, Bax and Bak function as the outer membrane component of the mitochondrial permeability pore in regulating necrotic cell death in mice, *eLife* 2 (2013) e00772.
- [75] J. Karch, O. Kanisicak, M.J. Brody, M.A. Sargent, D.M. Michael, J.D. Molkenint, Necroptosis interfaces with MOMP and the MPTP in Mediating Cell Death, *PLoS ONE* 10 (2015), e0130520.
- [76] M. Bonora, C. Giorgi, P. Pinton, Molecular mechanisms and consequences of mitochondrial permeability transition, *Nat. Rev. Mol. Cell Biol.* 23 (2022) 266–285.
- [77] X. Renaudin, Reactive oxygen species and DNA damage response in cancer, *Int. Rev. Cell Mol. Biol.* 364 (2021) 139–161.
- [78] H.K. Baumgartner, J.V. Gerasimenko, C. Thorne, P. Ferdek, T. Pozzan, A. V. Tepikin, O.H. Petersen, R. Sutton, A.J. Watson, O.V. Gerasimenko, Calcium elevation in mitochondria is the main Ca2+ requirement for mitochondrial permeability transition pore (mPTP) opening, *J. Biol. Chem.* 284 (2009) 20796–20803.
- [79] T.S. Luongo, J.P. Lambert, A. Yuan, X. Zhang, P. Gross, J. Song, S. Shanmughapriya, E. Gao, M. Jain, S.R. Houser, W.J. Koch, J.Y. Cheung, M. Madesh, J.W. Elrod, The mitochondrial calcium uniporter matches energetic supply with cardiac workload during stress and modulates permeability transition, *Cell Rep.* 12 (2015) 23–34.
- [80] J. Hamilton, T. Brustovetsky, N. Brustovetsky, The effect of mitochondrial calcium uniporter and cyclophilin D knockout on resistance of brain mitochondria to Ca(2+)–induced damage, *J. Biol. Chem.* 296 (2021), 100669.
- [81] T. Konig, S.E. Troder, K. Bakka, A. Korwiz, R. Richter-Dennerlein, P.A. Lampe, M. Patron, M. Muhlmeister, S. Guerrero-Castillo, U. Brandt, T. Decker, I. Lauria, A. Paggio, R. Rizzuto, E.I. Rugarli, D. De Stefani, T. Langer, The m-AAA protease associated with neurodegeneration limits MCU activity in mitochondria, *Mol. Cell* 64 (2016) 148–162.
- [82] J. Htoo, S. Lu, J.Q. Kwong, M.J. Brund, K.M. Grimes, M.A. Sargent, M.E. Brown, M.E. Davis, D.M. Bers, J.D. Molkenint, MCU induction protects the heart from postischemic remodeling, *Circ. Res.* 127 (2020) 379–390.
- [83] A.N. Antony, M. Paillard, C. Mofatt, E. Juskeviciute, J. Correnti, B. Bolon, E. Rubin, G. Csordas, E.L. Seifert, J.B. Hoek, G. Hajnoczky, MICU1 regulation of mitochondrial Ca(2+) uptake dictates survival and tissue regeneration, *Nat. Commun.* 7 (2016) 10955.
- [84] T.S. Luongo, J.P. Lambert, P. Gross, M. Nwokedi, A.A. Lombardi, S. Shanmughapriya, A.C. Carpenter, D. Kolmetzky, E. Gao, J.H. van Berlo, E. J. Tsai, J.D. Molkenint, X. Chen, M. Madesh, S.R. Houser, J.W. Elrod, The mitochondrial Na(+)/Ca(2+) exchanger is essential for Ca(2+) homeostasis and viability, *Nature* 545 (2017) 93–97.
- [85] X. Pan, J. Liu, T. Nguyen, C. Liu, J. Sun, Y. Teng, M.M. Ferguson, I.I. Rovira, M. Allen, D.A. Springer, A.M. Aponte, M. Gucek, R.S. Balaban, E. Murphy, T. Finkel, The physiological role of mitochondrial calcium revealed by mice

- lacking the mitochondrial calcium uniporter, *Nat. Cell Biol.* 15 (2013) 1464–1472.
- [86] T.P. Rasmussen, Y. Wu, M.L. Joiner, O.M. Koval, N.R. Wilson, E.D. Luczak, Q. Wang, B. Chen, Z. Gao, Z. Zhu, B.A. Wagner, J. Soto, M.L. McCormick, W. Kutschke, R.M. Weiss, L. Yu, R.L. Boudreau, E.D. Abel, F. Zhan, D.R. Spitz, G. R. Buettner, L.S. Song, L.V. Zingman, M.E. Anderson, Inhibition of MCU forces extramitochondrial adaptations governing physiological and pathological stress responses in heart, *Proc. Natl. Acad. Sci. U.S.A.* 112 (2015) 9129–9134.
- [87] R.J. Parks, S. Menazza, K.M. Holmstrom, G. Amanakis, M. Fergusson, H. Ma, A. M. Aponte, P. Bernardi, T. Finkel, E. Murphy, Cyclophilin D-mediated regulation of the permeability transition pore is altered in mice lacking the mitochondrial calcium uniporter, *Cardiovasc. Res.* 115 (2019) 385–394.
- [88] M. Bonora, C. Morganti, G. Morciano, G. Pedriali, M. Lebedzinska-Arciszewska, G. Aquila, C. Giorgi, P. Rizzo, G. Campo, R. Ferrari, G. Kroemer, M. R. Wieckowski, L. Galluzzi, P. Pinton, Mitochondrial permeability transition involves dissociation of F1FO ATP synthase dimers and C-ring conformation, *EMBO Rep.* 18 (2017) 1077–1089.
- [89] G. Pinke, L. Zhou, L.A. Sazanov, Cryo-EM structure of the entire mammalian F-type ATP synthase, *Nat. Struct. Mol. Biol.* 27 (2020) 1077–1085.
- [90] A. Carrer, L. Tommasin, J. Sileikyte, F. Piscato, R. Filadi, A. Urbani, M. Forte, A. Rasola, I. Szabo, M. Carraro, P. Bernardi, Defining the molecular mechanisms of the mitochondrial permeability transition through genetic manipulation of F-ATP synthase, *Nat. Commun.* 12 (2021) 4835.
- [91] R. Docampo, A.E. Vercesi, G. Huang, N. Lander, M.A. Chiurillo, M. Bertolini, Mitochondrial Ca(2+) homeostasis in trypanosomes, *Int. Rev. Cell Mol. Biol.* 362 (2021) 261–289.
- [92] G. Quarato, F. Llambi, C.S. Guy, J. Min, M. Actis, H. Sun, S. Narina, S.M. Prueitt-Miller, J. Peng, Z. Rankovic, D.R. Green, Ca(2+)-mediated mitochondrial inner membrane permeabilization induces cell death independently of Bax and Bak, *Cell Death Differ.* 29 (2022) 1318–1334.
- [93] S. Marchi, P. Pinton, Mitochondria in the line of fire, *Cell Death Differ.* 29 (2022) 1301–1303.
- [94] R. Weinlich, A. Oberst, H.M. Beere, D.R. Green, Necroptosis in development, inflammation and disease, *Nat. Rev. Mol. Cell Biol.* 18 (2017) 127–136.
- [95] L. Galluzzi, O. Kepp, F.K. Chan, G. Kroemer, Necroptosis: mechanisms and relevance to disease, *Annu. Rev. Pathol.* 12 (2017) 103–130.
- [96] M.I. Faizan, T. Ahmad, Altered mitochondrial calcium handling and cell death by necroptosis: an emerging paradigm, *Mitochondrion* 57 (2021) 47–62.
- [97] M. Nomura, A. Ueno, K. Saga, M. Fukuzawa, Y. Kaneda, Accumulation of cytosolic calcium induces necroptotic cell death in human neuroblastoma, *Cancer Res.* 74 (2014) 1056–1066.
- [98] J. Groenendyk, L.B. Agellon, M. Michalak, Calcium signaling and endoplasmic reticulum stress, *Int. Rev. Cell Mol. Biol.* 363 (2021) 1–20.
- [99] Y. Lv, G. Shao, Q. Zhang, X. Wang, Y. Meng, L. Wang, F. Huang, T. Yang, Y. Jin, C. Fu, The antimicrobial peptide PFR induces necroptosis mediated by ER stress and elevated cytoplasmic calcium and mitochondrial ROS levels: cooperation with Ara-C to act against acute myeloid leukemia, *Signal Transduct. Target. Ther.* 4 (2019) 38.
- [100] Z. Song, H. Song, D. Liu, B. Yan, D. Wang, Y. Zhang, X. Zhao, X. Tian, C. Yan, Y. Han, Overexpression of MFN2 alleviates sorafenib-induced cardiomyocyte necroptosis via the MAM-CaMKII $\delta$  pathway *in vitro* and *in vivo*, *Theranostics* 12 (2022) 1267–1285.
- [101] H. Zhao, X. Pan, Mitochondrial Ca(2+) and cell cycle regulation, *Int. Rev. Cell Mol. Biol.* 362 (2021) 171–207.
- [102] C. Li, Q. Ma, S. Toan, J. Wang, H. Zhou, J. Liang, SERCA overexpression reduces reperfusion-mediated cardiac microvascular damage through inhibition of the calcium/MCU/mPTP/necroptosis signaling pathways, *Redox Biol.* 36 (2020), 101659.
- [103] F. Zeng, X. Chen, W. Cui, W. Wen, F. Lu, X. Sun, D. Ma, Y. Yuan, Z. Li, N. Hou, H. Zhao, X. Bi, J. Zhao, J. Zhou, Y. Zhang, R.P. Xiao, J. Cai, X. Zhang, RIPK1 binds MCU to mediate induction of mitochondrial Ca(2+) uptake and promotes colorectal oncogenesis, *Cancer Res.* 78 (2018) 2876–2885.
- [104] P. Zhu, S. Hu, Q. Jin, D. Li, F. Tian, S. Toan, Y. Li, H. Zhou, Y. Chen, Ripk3 promotes ER stress-induced necroptosis in cardiac IR injury: a mechanism involving calcium overload/XO/ROS/mPTP pathway, *Redox Biol.* 16 (2018) 157–168.
- [105] X. Jiang, B.R. Stockwell, M. Conrad, Ferroptosis: mechanisms, biology and role in disease, *Nat. Rev. Mol. Cell Biol.* 22 (2021) 266–282.
- [106] M. Conrad, J.P. Angeli, P. Vandenabeele, B.R. Stockwell, Regulated necrosis: disease relevance and therapeutic opportunities, *Nat. Rev. Drug Discov.* 15 (2016) 348–366.
- [107] L. Pedrera, R.A. Espiritu, U. Ros, J. Weber, A. Schmitt, J. Stroh, S. Haiflinger, S. von Karstedt, A.J. Garcia-Saez, Ferroptotic pores induce Ca(2+) fluxes and ESCRT-III activation to modulate cell death kinetics, *Cell Death Differ.* 28 (2021) 1644–1657.
- [108] S. Xin, C. Mueller, S. Pfeiffer, V.A.N. Kraft, J. Merl-Pham, X. Bao, R. Feederle, X. Jin, S.M. Hauck, P. Schmitt-Kopplin, J.A. Schick, MS4A15 drives ferroptosis resistance through calcium-restricted lipid remodeling, *Cell Death Differ.* 29 (2022) 670–686.
- [109] T. Nakamura, M. Ogawa, K. Kojima, S. Takayanagi, S. Ishihara, K. Hattori, I. Naguro, H. Ichijo, The mitochondrial Ca(2+) uptake regulator, MICU1, is involved in cold stress-induced ferroptosis, *EMBO Rep.* 22 (2021) e51532.
- [110] A. Ballabio, J.S. Bonifacino, Lysosomes as dynamic regulators of cell and organismal homeostasis, *Nat. Rev. Mol. Cell Biol.* 21 (2020) 101–118.
- [111] F. Wang, R. Gomez-Sintes, P. Boya, Lysosomal membrane permeabilization and cell death, *Traffic* 19 (2018) 918–931.
- [112] A. Sumoza-Toledo, R. Penner, TRPM2: a multifunctional ion channel for calcium signalling, *J. Physiol.* 589 (2011) 1515–1525 (Lond.).
- [113] D.L. Medina, Lysosomal calcium and autophagy, *Int. Rev. Cell Mol. Biol.* 362 (2021) 141–170.
- [114] P. Pihan, F. Lisbona, J. Borronovo, S. Edwards-Jorquera, P. Nunes-Hasler, K. Castillo, O. Kepp, H. Urra, S. Saarnio, H. Vihinen, A. Carreras-Sureda, S. Forveille, A. Sauvat, D. De Giorgis, A. Pupo, D.A. Rodriguez, G. Quarato, A. Sagredo, F. Lourido, A. Letai, R. Latorre, G. Kroemer, N. Demareux, E. Jokitalo, M.L. Concha, A. Glavic, D.R. Green, C. Hetz, Control of lysosomal-mediated cell death by the pH-dependent calcium channel RECS1, *Sci. Adv.* 7 (2021) eabe5469.
- [115] T. Vanden Berghe, A. Linkermann, S. Jouan-Lanhouet, H. Walczak, P. Vandenabeele, Regulated necrosis: the expanding network of non-apoptotic cell death pathways, *Nat. Rev. Mol. Cell Biol.* 15 (2014) 135–147.
- [116] E. Gerace, A. Masi, F. Resta, R. Felici, E. Landucci, T. Mello, D.E. Pellegrini-Giampietro, G. Mannaioni, F. Moroni, PARP-1 activation causes neuronal death in the hippocampal CA1 region by increasing the expression of Ca(2+)-permeable AMPA receptors, *Neurobiol. Dis.* 70 (2014) 43–52.
- [117] H. Wu, Y. Li, Q. Zhang, H. Wang, W. Xiu, P. Xu, Y. Deng, W. Huang, D.O. Wang, Crocetin antagonizes parthanatos in ischemic stroke via inhibiting NOX2 and preserving mitochondrial hexokinase-1, *Cell Death Dis.* 14 (2023) 50.
- [118] H. Zhong, R. Song, Q. Pang, Y. Liu, J. Zhuang, Y. Chen, J. Hu, J. Hu, Y. Liu, Z. Liu, J. Tang, Propofol inhibits parthanatos via ROS-ER-calcium-mitochondria signal pathway *in vivo* and *in vitro*, *Cell Death Dis.* 9 (2018) 932.
- [119] L. Galluzzi, O. Kepp, C. Trojel-Hansen, G. Kroemer, Non-apoptotic functions of apoptosis-regulatory proteins, *EMBO Rep.* 13 (2012) 322–330.
- [120] A. Gross, S.G. Katz, Non-apoptotic functions of BCL-2 family proteins, *Cell Death Differ.* 24 (2017) 1348–1358.
- [121] C. Giorgi, A. Danese, S. Missiroli, S. Patergnani, P. Pinton, Calcium dynamics as a machine for decoding signals, *Trends Cell Biol.* 28 (2018) 258–273.
- [122] M.D. Bootman, G. Bultynck, Fundamentals of cellular calcium signaling: a primer, *Cold Spring Harb. Perspect. Biol.* 12 (2020).
- [123] M.J. Berridge, M.D. Bootman, H.L. Roderick, Calcium signalling: dynamics, homeostasis and remodelling, *Nat. Rev. Mol. Cell Biol.* 4 (2003) 517–529.
- [124] G. Thiel, A. Lesch, S. Rubil, T.M. Backes, O.G. Rossler, Regulation of gene transcription following stimulation of transient receptor potential (TRP) channels, *Int. Rev. Cell Mol. Biol.* 335 (2018) 167–189.
- [125] W.A. Catterall, Voltage-gated calcium channels, *Cold Spring Harb. Perspect. Biol.* 3 (2011), a003947.
- [126] S. Negri, P. Faris, F. Moccia, Endolysosomal Ca(2+) signaling in cardiovascular health and disease, *Int. Rev. Cell Mol. Biol.* 363 (2021) 203–269.
- [127] J. Yang, Z. Zhao, M. Gu, X. Feng, H. Xu, Release and uptake mechanisms of vesicular Ca(2+) stores, *Protein Cell* 10 (2019) 8–19.
- [128] M. Brini, E. Carafoli, The plasma membrane Ca(2+) ATPase and the plasma membrane sodium calcium exchanger cooperate in the regulation of cell calcium, *Cold Spring Harb. Perspect. Biol.* 3 (2011).
- [129] C. Giorgi, S. Marchi, P. Pinton, The machineries, regulation and cellular functions of mitochondrial calcium, *Nat. Rev. Mol. Cell Biol.* 19 (2018) 713–730.